SARS ‐ CoV ‐2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non‐ VOC Variants During the First Waves of the COVID ‐19 Pandemic in Norway
APMIS · 2025
DOI: 10.1111/apm.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, 2025. Verfasst von Gro Tunheim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Antibody Formation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody levels induced by SARS‐CoV‐2 infection have been reported to be associated with specific symptoms, disease severity, and viral load. In this study we investigated whether antibody responses were associated with virus type (Alpha B.1.1.7 or non‐variants of concern (non‐VOC)), viral load and clinical outcome in unvaccinated non‐hospitalized adults with PCR‐confirmed SARS‐CoV‐2 infection. Serum samples, questionnaires and symptom diaries were collected longitudinally (Day 0–180) between May 2020 and June 2021. IgG levels against ancestral Wuhan antigens and antibodies inhibiting RBD‐ACE2 interaction were measured by multiplex immunoassay and flowcytometry, respectively. Antibody neutralization assays were performed with B.1 and B.1.1.7 viruses. Viral load was measured by digital‐droplet PCR, and virus isolates were sequenced. Factors influencing IgG levels were investigated using Bayesian multilevel models. Alpha‐cases had 2.6–3.2‐fold higher IgG levels against RBD, nucleocapsid, and spike on Day 14, and higher antibody‐mediated inhibition of ACE2‐RBD interaction compared to non‐VOC cases. Alpha‐cases displayed 1.8‐ and 5.4‐fold higher neutralizing antibody titers than non‐VOC cases against B.1 and B1.1.7, respectively, but both non‐VOC and Alpha cases displayed the lowest ratio of binding to neutralizing antibodies against their infecting virus type. Alpha cases reported more symptoms than non‐VOC cases, but the severity of disease was similar. Nausea was significantly associated with higher IgG levels, while no association was found for viral load, despite Alpha cases having higher viral loads than non‐VOC cases. This study shows higher antibody responses induced by the more transmissible Alpha virus compared to earlier non‐VOC variants after mild SARS‐CoV‐2 infection. Reporting of nausea was positively associated with IgG levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Immunology, Oslo University Hospital and University of Oslo, Oslo, Norway.
ORCID-Profile: Gro Tunheim, Even Fossum, Anna Hayman Robertson
Zitieren
APA
Tunheim, G., Baranowska-Hustad, M., Lund-Johansen, F., Fossum, E., Bhandari, S., Kukule, L., Møller, T. K. R., Vikse, E. L., Bekkevold, T., Oftung, F., Robertson, A. H., & Næss, L. M. (2025). SARS ‐ CoV ‐2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non‐ VOC Variants During the First Waves of the COVID ‐19 Pandemic in Norway. APMIS. https://doi.org/10.1111/apm.70102
Vancouver
Tunheim G, Baranowska-Hustad M, Lund-Johansen F, Fossum E, Bhandari S, Kukule L, et al. SARS ‐ CoV ‐2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non‐ VOC Variants During the First Waves of the COVID ‐19 Pandemic in Norway. APMIS. 2025. doi:10.1111/apm.70102
BibTeX
@article{Tunheim2025,
author = {Tunheim, Gro and Baranowska-Hustad, Marta and Lund-Johansen, Fridtjof and Fossum, Even and Bhandari, Sabin and Kukule, Liva and Møller, Thea Kristine Rogne and Vikse, Elisabeth L and Bekkevold, Terese and Oftung, Fredrik and Robertson, Anna Hayman and Næss, Lisbeth M},
title = {SARS ‐ CoV ‐2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non‐ VOC Variants During the First Waves of the COVID ‐19 Pandemic in Norway},
journal = {APMIS},
year = {2025},
doi = {10.1111/apm.70102}
}
EUVIMED